Compass Therapeutics Quarterly Cash Flow Statement
NASDAQ: CMPXHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
0.6882+0.0097 (+1.43%)
At close: Nov 20, 4:00 PM ET · Delayed 15 min
Compass Therapeutics free cash flow
In the quarter ended Sep 30, 2026, Compass Therapeutics generated -$16.3 million of operating cash flow and spent $106,000 on capital expenditures. That left free cash flow of -$16.4 million.
Summary generated from market data by MetaCap's automated system. Methodology
Compass Therapeutics cash flow statement (quarterly)
| Quarter (USD) | Q3 20262026-09-30 | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | -27.17M | -25.15M | -18.32M | -15.72M | -14.26M | -19.88M | -16.63M | -15.03M | -10.48M | -13.08M | -10.79M | -13.41M |
| Net Income growth (YoY) | — | — | — | — | — | — | — | — | — | — | — | — |
| Depreciation & Amortization | 28.00K | 21.00K | 15.00K | 17.00K | 19.00K | 100.00K | 140.00K | 140.00K | 143.00K | 152.00K | 154.00K | 161.00K |
| Stock-Based Compensation | 4.01M | 4.82M | 5.07M | 1.82M | 1.24M | 2.79M | 2.51M | 2.24M | 2.20M | 2.12M | 2.00M | 1.60M |
| Change in Working Capital | 6.78M | 5.57M | -4.15M | 1.50M | 2.21M | 5.06M | 774.00K | 4.12M | -2.96M | 787.00K | -4.87M | 115.00K |
| Operating Cash Flow | -16.32M | -14.74M | -17.27M | -13.25M | -10.85M | -11.83M | -13.21M | -9.16M | -11.05M | -10.75M | -13.89M | -12.35M |
| Capital Expenditures | -106.00K | -176.00K | -82.00K | 0 | -7.00K | 0 | -18.00K | 0 | -44.00K | 0 | 0 | -9.00K |
| Investing Cash Flow | 22.33M | -4.98M | 38.43M | -3.38M | -95.16M | -6.36M | 11.59M | 15.37M | 29.02M | 6.48M | -4.10M | 6.31M |
| Financing Cash Flow | 0 | 0 | 3.37M | 1.06M | 129.36M | 0 | -815.00K | -94.00K | -2.00K | 1.00K | 17.43M | -158.00K |
| Net Change in Cash | 6.02M | -19.71M | 24.52M | -15.57M | 23.36M | -18.19M | -2.44M | 6.11M | 17.96M | -4.27M | -554.00K | -6.20M |
| Free Cash Flow | -16.42M | -14.91M | -17.35M | -13.25M | -10.86M | -11.83M | -13.23M | -9.16M | -11.10M | -10.75M | -13.89M | -12.36M |
This table shows 12 quarterly periods of Compass Therapeutics's cash flow statement, from Q3 2026 back to Q4 2023, across 12 line items including net income, depreciation & amortization, stock-based compensation. Values in USD; B = billions, M = millions. Fiscal periods follow CMPX's reporting calendar. What is a cash flow statement?